Seley Jane Jeffrie
Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, NY, USA.
J Diabetes Sci Technol. 2025 Jan 25:19322968251314522. doi: 10.1177/19322968251314522.
In an article in the , Backfish and coauthors examined the dose accuracy and reliability of the Tempo Pen and Tempo Smart Button connected insulin pen system. This study sponsored by Eli Lilly and Company found that this system met the International Organization for Standardization 11608-1:2014 requirements for dose accuracy at a range of doses, as well as the data transfer requirements after all injections. While these results are very encouraging, they were based on simulated human factors data while data from a human factors validation study where individuals successfully dialed and administered correct doses was not reported. There is a need for further studies in a variety of populations that would greatly benefit from this enhanced insulin pen technology to facilitate optimization of dose adjustments based on accurate and reliable insulin dosing data.
在《》杂志上的一篇文章中,Backfish及其合著者研究了Tempo Pen和Tempo Smart Button连接胰岛素笔系统的剂量准确性和可靠性。这项由礼来公司赞助的研究发现,该系统在一系列剂量下符合国际标准化组织11608-1:2014对剂量准确性的要求,以及所有注射后的数据传输要求。虽然这些结果非常令人鼓舞,但它们基于模拟的人为因素数据,而未报告来自个人成功拨打并注射正确剂量的人为因素验证研究的数据。需要在各种人群中进行进一步研究,这些人群将从这种增强型胰岛素笔技术中大大受益,以促进基于准确可靠的胰岛素给药数据优化剂量调整。